BOC Sciences provides early-stage formulation development and proof services that translate a research compound into a dosing-ready, reproducible formulation for preclinical evaluation. Working with limited API supply, we combine physicochemical characterization, preformulation screening, prototype design, and short-term performance assessment to select the most practical formulation for proof-of-concept studies. Our specialists balance scientific rigor with material efficiency, delivering a clear candidate recommendation and an actionable development plan that reduces risk before larger-scale investment.
Early-stage formulation development is the phase where a candidate molecule is converted into a first usable formulation to support pharmacokinetic, pharmacological, and safety studies. The goal is not a final commercial product but a reliable proof-of-concept formulation that delivers adequate and consistent exposure with the limited API available. This stage includes assessing the molecule's physicochemical properties, choosing an administration route, screening excipients and vehicles, preparing prototype formulations, and confirming that the formulation behaves as intended through in vitro and early in vivo evaluation. By resolving solubility, stability, and performance questions early, BOC Sciences helps clients select a formulation strategy that can be carried into later development.
BOC Sciences characterizes the API and identifies the factors most likely to limit formulation success before designing experiments.
We evaluate the practical route and dosage form options aligned with the study design and the physical form of the compound.
BOC Sciences screens suitable excipients and vehicles to improve solubility, stability, and dosing practicality for early studies.
We design and prepare prototype formulations in small batches, using only the API quantities available for early studies.
BOC Sciences confirms that each prototype remains physically and chemically suitable over the short study window required for early evaluation.
We consolidate results into a ranked recommendation and a complete data package that supports confident formulation selection.
BOC Sciences helps research teams move from API supply and physicochemical data to a proof-of-concept formulation with controlled solubility, stability, and dosing performance.
BOC Sciences develops research-ready prototypes across conventional and enabling dosage forms. Each project is scoped around the molecule, route, dose, available material, and proof-of-concept question rather than a fixed formulation package.
| Dosage Form Category | Early-Stage Development Scope |
| Oral Solutions and Suspensions | Vehicle, buffer, co-solvent, surfactant, complexing agent, viscosity modifier, and suspension stabilizer screening; evaluation of concentration, redispersibility, precipitation after dilution, palatability-related constraints, and short-term stability. |
| Capsules, Powder Blends, and Immediate-Release Tablets | Excipient compatibility, blend preparation, flow and compression assessment, disintegration, content uniformity, and oral solid dose prototype development for powder-filled capsules, mini-tablets, and simple tablet systems. |
| Parenteral Solutions and Suspensions | Concentration and vehicle feasibility, pH and osmolality adjustment, solubilizer selection, filtration recovery, particle control, syringeability, precipitation risk, and compatibility with the intended research administration procedure. |
| Emulsions and Lipid-Based Systems | Oil, surfactant, and co-surfactant selection; self-emulsifying behavior; droplet size, dilution robustness, drug loading, and physical stability assessment through focused emulsion formulation studies. |
| Suspensions and Nanosuspensions | Wetting, particle-size reduction, stabilizer selection, viscosity, sedimentation, redispersibility, dissolution, and dose-delivery assessment supported by our suspension formulation services. |
| Lyophilized and Reconstitutable Products | Bulking agent, cryoprotectant, and lyoprotectant screening; freeze-drying feasibility, cake appearance, reconstitution, moisture, concentration recovery, and post-reconstitution stability through targeted lyophilization services. |
| Topical and Semisolid Formulations | Vehicle and base selection for gels, creams, ointments, and dispersions; evaluation of solubility, viscosity, spreadability, phase behavior, release, and compatibility with the intended application surface. |
| Complex and Enabling Formulations | Early prototypes for amorphous solid dispersions, nanocrystals, cyclodextrin complexes, lipid nanoparticles, polymeric nanoparticles, depot systems, and controlled-release concepts requiring specialized formulation technologies. |
Share your candidate's physical form, available API quantity, target route, dose range, study window, and formulation concerns. Our specialists will design a material-efficient screening plan covering route selection, vehicle and excipient choice, prototype preparation, performance testing, and candidate recommendation.
We review molecular data, available API, administration route, dose, study design, target product attributes, current difficulties, and analytical readiness. Data gaps are converted into focused experiments, and the team agrees on candidate-selection criteria before screening starts.
Our scientists select formulation variables that address the identified risks, define an API-sparing matrix, and prepare prototypes under controlled conditions. Composition, preparation order, process settings, observations, and sample recovery are documented for comparison and repeatability.
Prototypes are evaluated using formulation-relevant analytical, in vitro, and, when appropriate, in vivo tests. Results are compared across concentration, stability, release, particle behavior, exposure, reproducibility, and practical handling to identify a lead and backup candidate.
Clients receive formulation compositions, preparation procedures, analytical results, candidate comparisons, known limitations, and a clear selection rationale. The report also identifies unresolved risks and recommends confirmatory work, process studies, or advanced formulation development.
Early programs often have only milligram-to-low-gram quantities available, yet multiple excipients, concentrations, and delivery approaches may need evaluation. BOC Sciences uses staged decision gates, microplate or small-vial screens, analytical methods with low sample consumption, and fractional experimental designs to reduce material demand. Broad screens first eliminate unsuitable regions; confirmatory prototypes then use the remaining API only on conditions with a realistic chance of meeting the project goal.
A formulation may appear clear at preparation but precipitate after dilution, temperature change, solvent loss, pH shift, or contact with a biological medium. We distinguish equilibrium-solubility limits from kinetic supersaturation and test buffers, co-solvents, surfactants, cyclodextrins, salts, polymers, lipid vehicles, and particle-based approaches. Dilution robustness, precipitation time, solid-state identity, concentration recovery, and performance testing guide selection of a strategy that remains usable under the intended study conditions.
Hydrolysis, oxidation, photolysis, adsorption, aggregation, particle growth, phase separation, crystallization, and moisture uptake can all reduce formulation performance. BOC Sciences maps the failure mode before adding stabilizers or changing dosage form. pH, oxygen exposure, antioxidants, chelators, surfactants, polymers, ionic strength, process temperature, headspace, and container contact are adjusted systematically, while orthogonal analytical methods distinguish chemical degradation from physical loss or sample-handling artifacts.
Variable dissolution, burst release, incomplete redispersion, changing particle size, or inconsistent exposure can arise from uncontrolled material attributes or preparation steps. We review API form and particle size, excipient grade, mixing sequence, shear, hydration, drying, storage, and administration technique. Performance tests are linked to process observations so the selected prototype includes not only a composition, but also a preparation procedure and operating ranges that can be reproduced in the next study.
Collaborate with BOC Sciences to connect developability assessment, route feasibility, excipient screening, prototype preparation, orthogonal testing, and proof-of-concept candidate ranking in one coordinated early-stage formulation program.
BOC Sciences combines physicochemical characterization, preformulation screening, prototype design, and performance testing in one workflow. This integration helps clients move from raw candidate data to a usable formulation without gaps, and supports better decisions when solubility, stability, and dose practicality must be considered together.
We design every project around the API quantity actually available, using micro-scale methods and prioritized experiments. This material-sparing approach is critical at the early stage, when resupply may be slow or costly, and helps clients obtain a reliable formulation without exhausting their compound.
Rather than choosing a formulation on solubility alone, we rank prototypes across exposure potential, stability, practicality, and material use. This balanced selection reduces the risk of choosing a formulation that performs in theory but fails in the real dosing study.
The early-stage formulation is not an endpoint. BOC Sciences provides guidance and support for carrying the selected formulation into later work, including late stage formulation development, scale-up, and analytical development and quality control.
Client Needs: A discovery team needed an oral prototype for a weakly basic small molecule with low aqueous solubility. Less than 2 g of API was available, and the team required a formulation that could support dose-escalation research without relying on a large solvent volume.
Challenges: The compound dissolved under acidic conditions but precipitated rapidly as pH increased. Early suspension batches also showed particle growth and variable dissolution, making exposure difficult to interpret.
Solution: We mapped the pH-solubility profile, confirmed solid-state conversion by XRPD, and screened 24 micro-scale conditions covering polymers, surfactants, cyclodextrins, and lipid vehicles. Six prototypes advanced to dilution and biorelevant dissolution testing. Two lead systems were prepared at larger scale and compared for concentration recovery, precipitation time, particle behavior, and short-term stability.
Outcome: The study identified a lead oral formulation and a suspension-based backup, with defined preparation instructions and clear evidence explaining why each candidate controlled precipitation better than the original vehicle.
Client Needs: A peptide research group required a parenteral proof-of-concept formulation at a higher concentration than its existing phosphate-buffered solution. The molecule aggregated during concentration and showed adsorption losses in standard sample tubes.
Challenges: Aggregation increased near neutral pH, while lower pH improved physical stability but accelerated oxidation. The available peptide quantity limited broad formulation screening and repeat freeze-thaw experiments.
Solution: We designed a 20-condition API-sparing screen spanning four buffers, two pH regions, selected amino acids, surfactants, antioxidants, and low-binding containers. SEC-HPLC, LC-MS, DLS, and concentration recovery were measured after agitation and freeze-thaw stress. Three prototypes were confirmed at target concentration, followed by administration-device recovery testing and a short comparative pharmacokinetic study.
Outcome: The selected prototype reduced aggregation and adsorption while maintaining chemical recovery, enabling the planned proof-of-concept study and defining the stability risks that required continued development.
The main goal is to convert a candidate molecule into an initial formulation that can be prepared reproducibly and used for meaningful research evaluation. Development typically defines the administration route, dosage form, target concentration, excipient system, and preparation procedure while identifying risks such as poor solubility, precipitation, degradation, adsorption, aggregation, or inconsistent release. The purpose is not to finalize the product. Instead, the work generates enough evidence to show that a formulation can meet the immediate study objective and provide a rational direction for subsequent optimization, process development, and stability assessment.
A proof-of-concept formulation should not be selected from solubility or visual appearance alone. Candidates are usually compared across several project-specific attributes, including achievable concentration, precipitation after dilution, chemical and physical stability, dissolution or release behavior, particle-size change, redispersibility, preparation repeatability, administration practicality, and pharmacokinetic performance when relevant. Pass-or-fail criteria, weighted scoring, or multi-attribute ranking can be used to compare prototypes transparently. The final recommendation should identify a lead and, when possible, a backup formulation while explaining the advantages, limitations, and unresolved risks associated with each option.
Important properties include aqueous and pH-dependent solubility, pKa, LogP or LogD, solid form, crystallinity, melting and thermal transitions, hygroscopicity, particle size, surface behavior, permeability, and chemical stability. Peptides, proteins, and oligonucleotides may also require evaluation of aggregation, adsorption, oxidation, deamidation, and freeze-thaw sensitivity. These data help determine whether screening should prioritize buffers, co-solvents, surfactants, polymers, lipids, complexing agents, solid dispersions, or particle-based systems. Understanding the molecule first reduces uninformative experiments and connects each formulation variable to a defined developability risk.
API requirements depend on the molecule type, analytical sensitivity, proposed dosage forms, number of variables, target concentration, and whether performance or pharmacokinetic studies are included. BOC Sciences can design a staged, material-sparing program around the quantity currently available. Microscale screens, shared controls, and early elimination criteria are used to remove unsuitable formulation regions before confirmatory prototypes are prepared. Clients do not need to define a fixed quantity before contacting us. Providing the available amount, expected resupply options, and highest-priority research questions allows our scientists to recommend a practical scope and testing sequence.
Useful starting information includes the molecular structure or sequence, salt or solid form, known solubility and stability data, available analytical methods, current API quantity, intended administration route, target dose or concentration, acceptable dosing volume, and research conditions. Clients should also describe any buffers, solvents, excipients, or preparation procedures already tested, together with observed precipitation, degradation, aggregation, adsorption, or release problems. BOC Sciences uses this information to identify data gaps and design a project-specific screening matrix, analytical strategy, prototype-selection criteria, and next-step plan without repeating experiments that have already provided reliable evidence.
BOC Sciences designed a focused screening matrix that addressed our solubility and stability concerns without wasting API. The logic was clear and the priorities matched what mattered most for our early study.
— Dr. Whitfield, Lead Formulation Scientist
We had very little compound to work with, and BOC Sciences planned every experiment around that constraint. They extracted a usable formulation from a small amount of material, which saved us from an expensive resupply.
— Whitaker, Project Manager, Drug Development
The candidate ranking was clear and easy to understand. BOC Sciences compared our prototypes across exposure, stability, and practicality, so we could see exactly why one formulation was recommended over the others.
— Dr. Lopez, Preclinical Research Scientist
Beyond the recommended prototype, BOC Sciences gave us a practical plan for what to consider in later development. That forward-looking guidance made the early-stage decision much easier for our team.
— Davis, Head of Formulation Development
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
